1. Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus.
- Author
-
Zhu, Jian, Han, Junfeng, Liu, Liehua, Liu, Yu, Xu, Wen, Li, Xiaomu, Yang, Lin, Gu, Yong, Tang, Wei, Shi, Yongquan, Ye, Shandong, Hua, Fei, Xiang, Guangda, Liu, Ming, Sun, Zilin, Su, Qing, Li, Xiaoying, Li, Yuxiu, Li, Yanbing, and Li, Hong
- Subjects
- *
TYPE 2 diabetes , *ISLANDS of Langerhans , *GLUCAGON-like peptide-1 receptor , *GLYCEMIC control , *GLUCAGON-like peptide-1 agonists , *CANAGLIFLOZIN - Abstract
Islet β-cell dysfunction is a basic pathophysiological characteristic of type 2 diabetes mellitus (T2DM). Appropriate assessment of islet β-cell function is beneficial to better management of T2DM. Protecting islet β-cell function is vital to delay the progress of type 2 diabetes mellitus. Therefore, the Pancreatic Islet β-cell Expert Panel of the Chinese Diabetes Society and Endocrinology Society of Jiangsu Medical Association organized experts to draft the " Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus." This consensus suggests that β-cell function can be clinically assessed using blood glucose-based methods or methods that combine blood glucose and endogenous insulin or C-peptide levels. Some measures, including weight loss and early and sustained euglycemia control, could effectively protect islet β-cell function, and some newly developed drugs, such as Sodium-glucose cotransporter-2 inhibitor and Glucagon-like peptide-1 receptor agonists, could improve islet β-cell function, independent of glycemic control. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF